A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (NCT06537414)
A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)
🩺 Plain-English Summary (8th-Grade Level)
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen. The study will also include an optional long-term follow-up (LTFU) extension stage for eligible participants.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (80 Sites)
Showing the first 25 of 80 sites.
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — San Jose, California
- GSK Investigational Site — Minneapolis, Minnesota
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Westmead, New South Wales
- GSK Investigational Site — Fitzroy, Victoria
- GSK Investigational Site — Brussels,
- GSK Investigational Site — Edegem,
- GSK Investigational Site — Ghent,
- GSK Investigational Site — Aracaju,
- GSK Investigational Site — Curitiba,
- GSK Investigational Site — Manaus,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Calgary, Alberta
- GSK Investigational Site — Ottawa, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Beijing,
- GSK Investigational Site — Chengdu,
- GSK Investigational Site — Guangzhou,
- GSK Investigational Site — Shanghai,
- GSK Investigational Site — Clichy,
- GSK Investigational Site — Créteil,
- GSK Investigational Site — Limoges,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Chronic Hepatitis B Virus Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.